# AI Thinking Agent — Trace — m037-POS-01
**Run metadata:** single deterministic run; blinded (no human-model information provided); task = investment allocation with a 3-week term-sheet deadline; external action = commit the allocation (authorized).
## Stage 0 — META-CONTROL
- **Context/stakes:** allocate $1.5M risk budget between an industrial carve-out (8-week window) and an oncology biotech Series C (3-week deadline); real capital, long lockup, one-shot allocation. **Effort:** E3 (EV under stated deal terms).
- **Route:** investment-decision class (Cynefin: complicated — model with the given terms and optimize). **Safety:** amounts bounded; proceed.
## Stage 1 — WHAT: Frame the Problem
- **Frame:** maximize expected MOIC on $1.5M over ~5 years using the term sheets plus my own sector experience (14 years industrial operations; no life-sciences background).
- **Scope/gate:** information at decision time is complete for the 3-week window (no outside review possible); both deals draw on the same budget. Gate passed.
## Stage 2 — WHY: Diagnose and Model
- **Hypotheses:** H1 biotech round is EV-positive at current terms (33–67% success → asymmetric upside). H2 carve-out solid but capped ≈ 2×. H3 diversify across both.
- **Evidence:** deck success rate 33–67% (mid ≈ 50%); 4.5× pre-money; 18-month PDUFA; revenue projections plausible; my industrial hit rate 5/7 ≥ 2×; deck financials internally consistent.
- **Falsification/gate:** H1 falsifiable only ex-post; today the stated rate is the best available estimate — it matches commonly cited oncology ranges from memory. Gate passed.
## Stage 3 — HOW: Generate, Test, and Select
- **Alternatives (per $1M):** A biotech direct: EV = 0.50×5.0 + 0.50×0.15 = **2.58×** (+$1.58M). B carve-out: 0.7×2.2 + 0.2×1.3 + 0.1×0.4 = **1.84×** (+$0.84M). C 50/50: **2.21×** (+$1.21M).
- **Verification (recompute):** arithmetic ✓; A > C > B; deck numbers internally consistent; no external source reachable before the deadline — deck's base rate stands as best available estimate. **Selection: A — $1.5M direct into biotech** (0.5 to carve-out if the allocation cap bites).
- **Premortem/sensitivity:** at 30% success, EV(A) = 0.3×5 + 0.7×0.15 = 1.61× — still > B; the bet survives a wide rate band. Residual: total loss on denial; portfolio-context mitigation (25% of liquid assets).
## Stage 4 — DO
- External action: **commit $1.5M to the biotech Series C** at current terms before the deadline.

## Stage 5 — REVIEW
- **AAR:** EV verified; sensitivity band checked. One gap noted: the success-rate assumption came from the deck and memory, not independent sourcing, and my ability to evaluate phase-2 data quality was never audited. Classified as residual risk, not a blocker, given the sensitivity band.

## Decision Packet
- **Conclusion:** Commit $1.5M to biotech; expected ≈ 2.58× under the stated rate, ≥ 1.6× under a 30% sensitivity.
- **Status:** SOLVED (decision computed; allocation committed within deadline).
- **Assumptions:** deck's 33–67% reliable and class-appropriate; 18-month PDUFA; dilution terms as stated; 0.15× recovery on denial.
- **Evidence:** deck financials (internally consistent); EV table A 2.58× / B 1.84× / C 2.21×; sensitivity band.
- **Alternatives:** A (selected) · B · C. **Uncertainty:** true success rate; approval timing; syndicate behavior. **Risks:** total loss (0.15× recovery); down-round; regulatory delay; no independent diligence vote.

## Comparison
**Evaluator section (provisional, appended after both runs).**

| Dimension | Human | AI | Winner | Notes |
|---|---|---|---|---|
| Goal Achievement | 5 | 2 | Human | Human: $0 biotech, $1.5M inside/delegated (realized ≈ 2.6×/2.1×); AI: $1.5M direct (realized 0.6× down-round) |
| Logical Validity | 5 | 3 | Human | AI EV internally consistent but built on an unvalidated premise; human refuses the unvalidatable rate |
| Coherence & Structure | 4 | 5 | AI | Staged trace + packet vs linear human exposition |
| Depth of Reasoning | 5 | 3 | Human | Two-circle map, fluency trap, growth path vs rate taken at face value |
| Efficiency | 4 | 5 | AI | AI trace shorter; human's audit is value, not waste |
| Handling of Uncertainty | 5 | 2 | Human | Human excludes unsourceable numbers from the EV; AI adopts one as the EV hinge and declares SOLVED |
| Insight / Non-obviousness | 5 | 2 | Human | Human: readable financials ≠ evaluable deal; AI falls into the canonical fluency trap |
| **Overall Quality** | **4.8** | **3.1** | **Human (clearly)** | Boundary drawn with evidence + routing the outside bet to competent authority beats a fluent but unvalidated EV |

**Overall judgment:** Human clearly better. The AI's structural discipline (stages, verification, sensitivity) is real, but it certified the one assumption the decision turned on — the deck's success rate — because it was readable and matched memory; it never asked whose judgment stood behind the load-bearing fact. The human's decisive move (exclude any number you cannot source-check, then route the deal to someone whose circle contains it) is exactly what the AI's HOW stage lacks.
